Amneal Pharmaceuticals (NASDAQ:AMRX) Stock Price Down 5.5% - Time to Sell?

Key Points

• Shares fell 5.5%, trading as low as $13.32 and last at $13.15 on Monday, with volume of 751,873 shares (about 69% below the average session volume) after a prior close of $13.91.
• Analyst sentiment is a “Moderate Buy” (six Buy, two Hold) with a consensus price target of $15; recent notes include Zacks cutting to Hold while Truist raised its target to $17 and UBS initiated coverage with a $19 Buy.
• Amneal is a diversified generics and specialty pharmaceutical company with a market cap of $4.17B and a P/E of 18.3; its 50‑day and 200‑day SMAs are $13.23 and $12.49 respectively, and institutions own about 31.8% of the stock.

Shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Get Free Report) traded down 5.5% during trading on Monday . The stock traded as low as $13.32 and last traded at $13.15. 751,873 shares changed hands during trading, a decline of 69% from the average session volume of 2,412,776 shares. The stock had previously closed at $13.91.

Wall Street Analyst Weigh In

Several analysts have recently commented on the company. Zacks Research cut Amneal Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a report on Monday, April 6th. Truist Financial increased their target price on Amneal Pharmaceuticals from $15.00 to $17.00 and gave the stock a "buy" rating in a report on Monday, March 2nd. UBS Group started coverage on Amneal Pharmaceuticals in a report on Friday. They set a "buy" rating and a $19.00 target price on the stock. Finally, Weiss Ratings reiterated a "hold (c)" rating on shares of Amneal Pharmaceuticals in a research report on Wednesday, January 21st. Six investment analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. Based on data from MarketBeat.com, Amneal Pharmaceuticals presently has an average rating of "Moderate Buy" and a consensus price target of $15.00.

Amneal Pharmaceuticals Stock Performance

The stock has a market capitalization of $4.17 billion, a P/E ratio of 18.30 and a beta of 1.32. The stock has a 50-day simple moving average of $13.23 and a 200 day simple moving average of $12.49.

Hedge Funds Weigh In On Amneal Pharmaceuticals

A number of hedge funds and other institutional investors have recently bought and sold shares of AMRX. Kemnay Advisory Services Inc. bought a new position in Amneal Pharmaceuticals in the fourth quarter valued at approximately $26,000. Federated Hermes Inc. boosted its stake in Amneal Pharmaceuticals by 1,680.6% in the fourth quarter. Federated Hermes Inc. now owns 2,297 shares of the company's stock valued at $29,000 after acquiring an additional 2,168 shares during the last quarter. Comerica Bank boosted its stake in Amneal Pharmaceuticals by 186.7% in the third quarter. Comerica Bank now owns 3,005 shares of the company's stock valued at $30,000 after acquiring an additional 1,957 shares during the last quarter. Exchange Traded Concepts LLC bought a new position in Amneal Pharmaceuticals in the third quarter valued at approximately $31,000. Finally, Spire Wealth Management boosted its stake in Amneal Pharmaceuticals by 66.6% in the fourth quarter. Spire Wealth Management now owns 2,558 shares of the company's stock valued at $32,000 after acquiring an additional 1,023 shares during the last quarter. 31.82% of the stock is owned by institutional investors.

Amneal Pharmaceuticals Company Profile

Amneal Pharmaceuticals, Inc is a publicly traded integrated healthcare company specializing in the development, manufacturing and distribution of generic and specialty pharmaceutical products. The company’s portfolio includes oral solids, injectables, transdermals and biosimilars, serving a broad range of therapeutic areas such as cardiovascular, neuroscience, oncology and women’s health. Alongside its generic offerings, Amneal has built a branded portfolio through strategic acquisitions and internal development, positioning itself across both high-volume generics and higher-value specialty treatments.

Since its founding in 2002 by brothers Chirag and Chintu Modgil, Amneal has pursued growth through organic investment in research and development as well as targeted M&A.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.